India is home to the third largest HIV epidemic in the world — 3.14 million people are living with HIV, and yet the country has made extraordinary progress: new infections have fallen by nearly 50% since 2010, AIDS-related deaths have dropped by over 80%, and free antiretroviral therapy (ART) now reaches more than 18 lakh people. The tragedy is that stigma, misinformation, and fear of testing still keep hundreds of thousands of Indians from accessing a treatment programme that is, by any measure, among the most successful public health interventions in the country's history.
This guide explains how HIV works in the body, who is most at risk in India, where to get free and confidential testing, what NACO's treatment programme offers, which blood tests monitor HIV, and how people living with HIV in India can lead long, healthy lives.
HIV and AIDS: Understanding the Basics
HIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system — specifically, CD4 T-cells, the white blood cells that coordinate the immune response. Over time, as CD4 counts fall, the immune system becomes unable to fight off infections and cancers that a healthy body handles easily.
AIDS (Acquired Immunodeficiency Syndrome) is the late stage of HIV infection, diagnosed when:
- The CD4 count falls below 200 cells/µL (normal: 500–1,500 cells/µL), or
- Certain AIDS-defining illnesses appear (e.g., tuberculosis, pneumocystis pneumonia, cryptococcal meningitis, Kaposi's sarcoma)
Critical point: With modern treatment, the vast majority of people living with HIV in India today never progress to AIDS. HIV is now managed as a chronic condition, like diabetes or hypertension.
How HIV Spreads (and How It Does NOT)
HIV is transmitted through specific body fluids: blood, semen, vaginal and rectal fluids, and breast milk. In India, the most common transmission routes are:
| Route | Percentage of New Infections |
|---|---|
| Heterosexual contact | ~80% |
| Injection drug use (shared needles) | ~7% (very high in Manipur, Nagaland) |
| Male-to-male sexual contact | ~8% |
| Mother-to-child (vertical transmission) | ~4% |
| Blood transfusion / needle stick | <1% (with India's blood safety improvements) |
HIV does NOT spread through: casual contact, handshakes, hugging, sharing food or utensils, mosquito or insect bites, saliva (unless both parties have open sores and exchange blood), or sharing toilets.
HIV in India: Who Is at Risk?
India's epidemic is concentrated, not generalised — meaning HIV prevalence in the general population (0.20%) is low, but significantly higher in certain populations and geographies.
High-Prevalence States
- Northeastern states: Manipur, Mizoram, and Nagaland have adult HIV prevalence 3–5 times the national average, heavily linked to injection drug use.
- Southern states: Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu have historically higher prevalence, particularly among sex workers, truck drivers, and migrant populations.
- Maharashtra and Gujarat: Urban centres like Mumbai have sizeable at-risk populations.
Key Affected Populations
- Female sex workers (FSW): HIV prevalence approximately 1.8%, declining but still significant
- Men who have sex with men (MSM): HIV prevalence approximately 2.4%
- Transgender persons: Among the highest-risk groups; prevalence estimated at 3–4%
- People who inject drugs (PWID): Prevalence reaches 7–9% in northeastern India
- Long-distance truck drivers and migrant workers: Mobile populations with high-risk exposure
Even if you don't belong to these groups, anyone who has had unprotected sex with a new partner, shared needles, or received an unscreened blood product should consider getting tested — especially since India's HIV epidemic is transitioning, with a growing share of new infections occurring within married couples.
Knowing Your Status: HIV Testing in India
The single most important step in HIV control is knowing your status. In India, HIV testing is free, confidential, and widely available.
Where to Get Tested (Free)
Integrated Counselling and Testing Centres (ICTCs) are the backbone of India's HIV testing network. There are over 26,000 ICTCs across India, attached to government hospitals, community health centres, and primary health centres. Services at ICTCs are completely free and confidential.
| Facility Type | Services Offered |
|---|---|
| ICTC at government hospital | HIV counselling + testing, free |
| Facility ICTC (FICTC) | Antenatal HIV testing for pregnant women |
| Community ICTC (C-ICTC) | Outreach testing in high-risk communities |
| Standalone testing centres | Available in many cities |
You do not need a doctor's referral to walk into an ICTC. You can also get tested at private labs like SRL Diagnostics, Dr. Lal PathLabs, and Thyrocare — though you will pay for the test. Test costs at private labs typically range from ₹200 to ₹800 depending on the type of test ordered.
HIV Tests: What They Are and How They Work
1. HIV Rapid Antigen-Antibody Test (HIV Ag/Ab Combo)
- What it detects: Both HIV antibodies (immune response) and HIV p24 antigen (viral protein)
- Window period: 18–45 days after exposure
- How long: Results in 20–30 minutes
- Where: ICTCs, many private labs, home kits (now available in India)
2. ELISA / 4th Generation Combo Test
- Higher sensitivity than rapid test; used for confirmation
- Detects both Ag and Ab
- Window period: 18–45 days
3. Western Blot / Line Immunoassay
- Confirmatory test — used only if ELISA is reactive
- Very high specificity
4. HIV Viral Load (RNA PCR)
- Quantifies the amount of HIV in the blood (copies/mL)
- Used for diagnosis of acute HIV (before antibodies form) and for monitoring treatment response
- Not used for initial screening — ordered by doctors after diagnosis
5. CD4 Count
- Counts CD4 T-cells per microlitre of blood
- Normal range: 500–1,500 cells/µL
- Critical threshold for treatment initiation: In India, ART is now offered to ALL HIV-positive individuals regardless of CD4 count (since 2017)
- CD4 <200 = AIDS-defining threshold
Upload your HIV test reports, CD4 counts, and viral load reports to MedicalVault to maintain a clear longitudinal record — essential for monitoring your treatment response over months and years.
Understanding the Window Period
Every HIV test has a window period — the time between HIV infection and when the test can reliably detect it. During this window, a person is infected and infectious but will test negative.
| Test Type | Window Period |
|---|---|
| 4th Gen Ag/Ab combo test | 18–45 days |
| 3rd Gen antibody-only test | 45–90 days |
| Home rapid tests (most available in India) | 25–45 days |
If you have had a recent high-risk exposure (within the last 72 hours), do not test — seek PEP immediately (see below). If exposure was 3–12 weeks ago, test — but if negative, repeat at 45 days from exposure for certainty.
NACO's Free Treatment Programme
The National AIDS Control Organisation (NACO), under the Ministry of Health and Family Welfare, runs what is now one of the most expansive free HIV treatment programmes in the world.
Free ART at Government ART Centres
India has over 600 ART (Antiretroviral Therapy) centres at government medical colleges and district hospitals, plus more than 1,300 Link ART Centres for stable patients to collect medicines closer to home.
What is free:
- All ART medications — including newer regimens (see below)
- CD4 count testing every 6 months
- Viral load testing every 12 months (free at NACO facilities)
- Treatment for opportunistic infections at government hospitals
- Counselling services
How to enrol: Visit your nearest government ART centre with proof of ID (Aadhaar is accepted). You will be counselled, tested, and if HIV-positive, enrolled. There is no charge for any of this.
Modern ART Regimens in India
India has progressively upgraded its first-line ART regimen. The current standard for most adults is a single daily tablet containing:
TLD (Tenofovir + Lamivudine + Dolutegravir)
This three-in-one tablet has dramatically improved treatment — dolutegravir-based regimens have high efficacy, a high genetic barrier to resistance, and excellent tolerability. NACO began rolling out TLD (branded as Dolutegravir combo or the combination available at ART centres) as the preferred first-line regimen from 2021 onwards.
For those on the older TLE (Tenofovir + Lamivudine + Efavirenz) regimen, NACO has been transitioning patients to TLD systematically.
NACP Phase V: India's 2021–2026 HIV Strategy
The National AIDS Control Programme Phase V sets ambitious targets:
- 80% reduction in new HIV infections and AIDS deaths from 2010 baseline by 2025–26
- 95-95-95 targets: 95% of PLHIV know their status → 95% of those on ART → 95% of those with suppressed viral load
India's progress as of 2025:
- ~92% of PLHIV know their status
- ~88% of those diagnosed are on ART
- ~97% viral suppression among those on ART
The viral suppression rate is world-class — a testament to India's generic drug manufacturing capability and the dedication of NACO's network. The gap remains in getting more people tested and into treatment.
HIV and TB: India's Dual Epidemic
India carries one of the highest burdens of both HIV and TB in the world, and the two diseases are deeply intertwined. TB is the leading opportunistic infection and cause of death in people living with HIV in India — people with HIV are 18 times more likely to develop active TB.
NACO and the Revised National TB Control Programme (now National TB Elimination Programme) work jointly to:
- Test all TB patients for HIV at diagnosis
- Test all HIV-positive individuals for TB (including latent TB)
- Provide both ART and anti-TB drugs to co-infected patients
If you are HIV-positive, ensure you are screened for TB at regular intervals. See our TB treatment guide for more on India's TB elimination programme.
PEP and PrEP: Prevention After and Before Exposure
PEP (Post-Exposure Prophylaxis)
PEP is an emergency medication taken after a potential HIV exposure to prevent infection. It must be started within 72 hours of exposure — ideally within 24 hours.
- Available at most government hospitals with ART centres
- Course: 28 days of ART medications
- Highly effective if taken correctly and promptly
- Also available at private hospitals (at cost)
When to seek PEP immediately:
- Unprotected sex with a person of unknown or positive HIV status
- Needle-stick injury in healthcare workers
- Sexual assault
PrEP (Pre-Exposure Prophylaxis)
PrEP is a daily HIV prevention medication for HIV-negative individuals at high ongoing risk. The drug Tenofovir + Emtricitabine (TDF/FTC, internationally known as Truvada) taken daily reduces HIV acquisition risk by up to 99% in people who take it consistently.
India launched a government PrEP programme through NACO and select NGOs in 2023–2024, targeting high-risk populations. Private prescriptions of generic TDF/FTC are also available through infectious disease specialists at a cost of approximately ₹800–₹1,500/month — far cheaper than global prices due to Indian generic manufacturing. Discuss PrEP with a doctor at any HIV specialist clinic or ART centre.
Living With HIV in India: Long-Term Health Management
A person who starts ART early and maintains an undetectable viral load can expect a near-normal life expectancy. The key principle is U=U: Undetectable = Untransmittable — a person with an undetectable viral load (achieved with consistent ART) cannot sexually transmit HIV to a partner. This is medically established and endorsed by NACO and international health bodies.
Monitoring Tests on ART
| Test | Frequency | Purpose |
|---|---|---|
| Viral load (HIV RNA) | Every 12 months (every 6 months initially) | Confirms ART is working; undetectable goal |
| CD4 count | Every 6 months initially, annually if stable | Immune function monitoring |
| Complete Blood Count (CBC) | Every 6 months | Check for anaemia, low WBC |
| Kidney Function Tests (KFT) | Annually | Tenofovir can affect kidneys |
| Liver Function Tests (LFT) | Annually | Monitor liver health |
| Lipid profile | Annually | Some ART drugs affect cholesterol |
| Fasting blood sugar | Annually | Screen for diabetes (increased risk on ART) |
| Hepatitis B & C screening | At diagnosis | Co-infection common; affects ART choice |
| TB screening | Every visit | High TB-HIV co-morbidity |
Track all these tests in MedicalVault and use trend analysis to monitor your CD4 count trajectory and viral load over time — essential for conversations with your HIV physician.
Addressing Stigma
Stigma remains the single greatest barrier to HIV care in India. People fear discrimination by family, employers, and healthcare providers. Key facts to counter stigma:
- HIV is not spread through casual contact — not through sharing food, hugging, or coughing
- A person on ART with an undetectable viral load cannot transmit HIV sexually
- HIV-positive individuals can marry, have biological children, and live full professional and personal lives
- Discrimination based on HIV status is illegal in India under the HIV and AIDS (Prevention and Control) Act, 2017
The HIV and AIDS (Prevention and Control) Act, 2017 makes it a criminal offence to discriminate against PLHIV in employment, healthcare, housing, or education. You can report violations to the State AIDS Control Society (SACS) in your state.
Mental Health and HIV
Living with a chronic condition under societal stigma increases the risk of depression and anxiety. These are real medical conditions that need treatment — not signs of weakness. NACO's ICTC network provides counselling services, and there are NGOs like NNPHIV (National Network of Positive People Living with HIV) that offer peer support, support groups, and advocacy. See our mental health guide for more on managing depression and anxiety in the Indian context.
Key Takeaways
- India has 3.14 million people living with HIV, but new infections have fallen by nearly 50% since 2010 — one of the world's great public health successes.
- HIV is transmitted through specific body fluids (blood, semen, breast milk) — NOT through casual contact, mosquitoes, or shared utensils.
- Free, confidential HIV testing is available at 26,000+ ICTCs across India — no referral or appointment needed.
- Know the window period: test at least 45 days after any high-risk exposure for a reliable result.
- If you have had a potential exposure in the last 72 hours, seek PEP immediately at any government hospital — do not wait.
- Free ART (including the modern Tenofovir + Lamivudine + Dolutegravir regimen) is available at 600+ government ART centres with no charge for medications, CD4 tests, or viral load monitoring.
- HIV co-infection with TB is a major concern in India — always screen for both.
- Discrimination against PLHIV is illegal under India's 2017 HIV Act; U=U means an undetectable person cannot transmit HIV.
- Keep all CD4 counts, viral loads, and related blood test reports organised in MedicalVault for seamless long-term monitoring and doctor consultations.